Literature DB >> 8459870

Successful control of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis using magnesium carbonate and calcium carbonate as phosphate binders.

V Parsons1, D Baldwin, C Moniz, J Marsden, E Ball, I Rifkin.   

Abstract

To avoid the use of aluminium as a phosphate binder, patients on CAPD who were stable were dialysed against a peritoneal dialysis fluid which was magnesium free. A mixture of calcium and magnesium carbonate was used as a phosphate binder over a period in excess of 1 year. Vitamin D analogues were used in the majority. Results show satisfactory control of hyperparathyroidism with mean parathyroid hormone concentration for the group of 121 pg/ml (normal < 100 pg/ml), calcium concentration of 2.41 mmol/l, magnesium 0.97 mmol/l, phosphate 1.36 mmol/l and aluminium 0.35 mmol/l (normal < 0.2 mumol/l). These results were as good as and better in some respects than a minority using calcium carbonate alone or remaining on aluminium hydroxide, the latter remaining on Mg-containing CAPD fluid.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8459870     DOI: 10.1159/000187238

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

Review 1.  Hyperphosphataemia in renal failure: causes, consequences and current management.

Authors:  Fouad Albaaj; Alastair Hutchison
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease?

Authors:  Mingxin Wei; Khaled Esbaei; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

3.  MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial.

Authors:  Baigalmaa Evsanaa; Irene Liu; Babak Aliazardeh; Sara Mahdavi; Gursarn Bajwa; Jerry Gula; Michelle Tam; Elena Sze; Janet M Roscoe; Paul Y Tam; Tabo Sikaneta
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

Review 4.  Beneficial effects of magnesium in chronic renal failure: a foe no longer.

Authors:  Ioannis P Tzanakis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2008-12-30       Impact factor: 2.370

5.  Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.

Authors:  Christopher W McIntyre; Pearl Pai; Graham Warwick; Martin Wilkie; Alex J Toft; Alastair J Hutchison
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 8.237

6.  Use of magnesium as a drug in chronic kidney disease.

Authors:  Alastair J Hutchison; Martin Wilkie
Journal:  Clin Kidney J       Date:  2012-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.